• About Us
  • Privacy
  • Contact Us

Contact Lens Update

Clinical Insights Based in Current Research

Search Our Site

  • Home
  • Browse Past Issues
  • Resource Library
  • Back to Basics
  • Useful Links
  • About Us
  • Contact Us

Conference Highlights

Evidence-Based Efficacy of Myopia Control Interventions

April 18th, 2019
Noel Brennan headshot_webDr Noel A. Brennan is Research Fellow at Johnson & Johnson Vision, where he has been since 2011.  Prior to that he co-directed a privately-owned research consulting company and, before that, was an academic faculty member at the University of Melbourne, reaching the level of Reader.

Download the poster (.pdf), which was originally shared at the American Academy of Optometry (AAO) annual meeting, 2018.


Evidence-Based Efficacy of Myopia Control Interventions
Noel A. Brennan1 MScOptom, PhD, FAAO Xu Cheng1 MD, PhD, FAAO Mark Bullimore2 MCOptom, PhD, FAAO, FARVO
1. Johnson & Johnson Vision
2. Independent Consultant

Purpose
Decision-making in modern clinical practice is increasingly dependent on evidence-based medicine. Previous analyses of the efficacy of myopia control interventions have delivered results as percentage or absolute reduction in myopia progression over a given time frame. Estimates of longer term efficacy have been constructed around these estimates but fail to account for two important recent observations: (i) myopia control efficacy tends to an absolute effect rather than a relative effect across the progression range, and (ii) efficacy may decrease over time on both absolute and relative bases. Here, we apply the principles of evidence-based medicine to efficacy of myopia control interventions.

Methods
We systematically reviewed the literature, including relevant peer-reviewed conference abstracts, to categorize quality of investigations of a set of myopia control interventions currently of interest (see Table) based on adherence to evidence-based principles. The only indisputable metric than can be used is data-driven estimates of cumulative absolute reduction in progression rather than absolute annual or relative rates. The primary variable should be reduction in axial elongation because of its assumed relevance to disease development but refractive error serves as an important secondary endpoint. We also identified maximum efficacy outcomes of each category of intervention.

Results
The table shows the classification of 32 identified studies according to quality of evidence. Study designs to the left in the table represent more rigorous levels of evidence. Despite the popularity of low-dose (0.01%) atropine, there is no direct evidence of a reduction in axial elongation with this intervention. Orthokeratology (in a cohort study) and spectacles (in a controlled, randomized study with selective inclusion criteria) have provided the largest recorded treatment effects. Soft, multizone lenses have the greatest weight of evidence but do not demonstrate superior performance possibly because of insufficient study periods. Increased time outdoors alone does not provide a large treatment effect but may be a useful adjunct therapy. It should be noted that rebound was not examined in any of studies except for one cohort study with low-dose atropine.

Conclusion
The maximum treatment effect that can currently be supported is 0.43mm for axial elongation and 1.05D for refractive error; however, such efficacy may be restricted to a subset of patients and rebound cannot be ruled out. Any suggestions of greater potential efficacy are speculative and not evidence-based. This analysis establishes a precedent for evidence-based reporting of myopia control interventions.

Related Articles

  • April 18, 2019

    The International Myopia Institute White Paper Reports – a landmark moment

  • April 18, 2019

    Summary: The International Myopia Institute Report

  • April 18, 2019

    Evidence-Based Efficacy of Myopia Control Interventions

  • April 18, 2019

    Practitioner Reference: Applying the clinical management guidelines

Issues

  • Multifocal Contact Lenses
  • Artificial Tears: An Update
  • Myopia: New Evidence and Best Practices
  • Neuropathic Pain
  • Specialty Rigid Lenses
  • Contact lens compliance
  • Pandemic update
  • Digital Devices and Dry Eye: A Growing Issue
  • The long and short of axial length
  • Using BCLA CLEAR with your patients
  • Helping your patients through allergy season
  • Getting the measure of meibomian glands
  • 2020: An extraordinary year
  • Scleral lens update
  • A dose of myopia
  • New news since TFOS DEWS II
  • COVID-19 Special Edition
  • Material considerations
  • Putting dry eye theory into practice
  • Getting started with Ortho-K
  • Infiltrates – an update
  • Staining
  • Myopia matters: Summarising the IMI reports
  • Lids and contact lenses
  • Myths
  • Revisiting patient compliance
  • Contact Lenses & Kids
  • Interprofessional Collaboration
  • Digital eye strain
  • New Dry Eye Technology
  • Update on Presbyopia
  • Taking stock of dry eye disease: DEWS II
  • Scleral Lenses
  • Pain and Sensation
  • Lab measurements in clinical practice
  • Control of pediatric myopia
  • Nutrition
  • Rethinking contact lens deposits
  • Extended wear
  • Daily Disposables
  • Eyelash Mites (Demodex)
  • Outsmarting bacteria with new technology
  • Youth and contact lenses
  • Sports Vision
  • Ocular effects of UV radiation from the sun
  • Eyelid Conditions
  • Makeup: Impact on ocular health
  • Myopia Control – Update 2014
  • The Growing Prevalence of Myopia
  • Cosmetic contact lenses
  • Contact lens discomfort – The essentials
  • Technology and contact lens research
  • It's A Question of Comfort
  • Contact lens materials
  • Let's talk about SICS
  • Conjunctival Controversies
  • Kids & Contact Lenses
  • One-day silicone hydrogel lenses
  • Solutions
  • Spotlight on Scleral lenses
  • Drug delivery via contact lenses
  • Ocular allergies
  • Reducing lens case contamination
  • Dry eye and meibomium gland dysfunction
  • Myopia Control
  • Presbyopia
  • Compliance and non-compliance
  • Lens care
  • Celebrating 50 years of contact lenses

Looking for another article?

Alcon coopervision Johnson&Johnson Vision Care

Newsletter Sign-Up

Sign-up for and start receiving our newsletter.

Site Map

  • Home
  • Browse Past Issues
    • Editorial
    • Feature Article
    • Clinical Insight
    • Conference Highlights
  • Resource Library
  • Back to Basics
  • Useful Links
  • About Us
  • Contact Us
© 2023 Contact Lens Update